- Home
- IBRX vs UGI Comparison
IBRX vs UGI Comparison
Compare IBRX & UGI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | IBRX | UGI |
|---|---|---|
| Founded | 2014 | 1940 |
| Country | United States | United States |
| Employees | N/A | 9400 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Natural Gas Distribution |
| Sector | Health Care | Utilities |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.5B | 7.8B |
| IPO Year | 2015 | N/A |
Fundamental Metrics
Financial Performance| Metric | IBRX | UGI |
|---|---|---|
| Price | $7.41 | $36.78 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 1 |
| Target Price | $12.57 | ★ $44.00 |
| AVG Volume (30 Days) | ★ 14.7M | 1.2M |
| Earning Date | 05-11-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 4.03% |
| EPS Growth | ★ 38.71 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $113,288,000.00 | N/A |
| Revenue This Year | $88.59 | $8.88 |
| Revenue Next Year | $131.15 | $2.27 |
| P/E Ratio | ★ N/A | $14.04 |
| Revenue Growth | ★ 668.31 | N/A |
| 52 Week Low | $1.83 | $31.62 |
| 52 Week High | $12.43 | $41.34 |
Technical Indicators
Market Signals| Indicator | IBRX | UGI |
|---|---|---|
| Relative Strength Index (RSI) | 46.98 | 49.03 |
| Support Level | $2.22 | $35.55 |
| Resistance Level | $8.28 | $37.32 |
| Average True Range (ATR) | 0.56 | 0.74 |
| MACD | 0.06 | -0.03 |
| Stochastic Oscillator | 39.03 | 40.96 |
Price Performance
Historical ComparisonAbout IBRX ImmunityBio Inc.
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.
About UGI UGI Corporation
UGI Corp is an American holding company that, through its subsidiaries, is involved in the transport and marketing of energy and related services. Its segments include AmeriGas Propane, UGI International, Midstream & Marketing, and Utilities. The AmeriGas Propane segment consists of the propane distribution business. The UGI International segment consists of LPG distribution businesses. The Midstream & Marketing segment consists of energy-related businesses. The Utilities segment consists of the regulated natural gas and electric distribution. The company derives a majority of its revenue from the UGI International segment.